Sevenless Therapeutics Ltd. has disclosed son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, pain, dementia, Noonan syndrome, Parkinson's disease and neurofibromatosis type 1.

Gachon University has divulged quinoxaline compounds acting as proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) and its mutant inhibitors reported to be useful for the treatment of cancer.

Synnovation Therapeutics Inc. has prepared and tested phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer and more.

Windermere Therapeutics Inc. has disclosed new GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.

Histone acetyltransferase p300 (EP300) inhibitors have been reported in a Kronos Bio Inc. patent and are described as potentially useful for the treatment of cancer and inflammatory disorders.

Hitgen Ltd. has prepared and tested interleukin-17 receptor A (IL17RA; CD217) antagonists reported to be useful for the treatment of autoimmune disease, cancer, infections, asthma, multiple sclerosis, psoriasis, rheumatoid arthritis and inflammatory disorders.

A Gilva Therapeutics Co. Ltd. patent describes new quinazolinone derivatives acting as histone deacetylase 6 (HDAC6) inhibitors.

Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

Fudan University has described new polyphenol compounds reported to be useful for the treatment of ischemic stroke.

Work at The Cleveland Clinic Foundation has led to the identification of new 3β-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 1 (3β-HSD1, HSD3B1) inhibitors reported to be useful for the treatment of cancer.